A 157378.0,
A-157378.0,
A157378.0,
ABT 378,
ABT-378,
ABT378,
lopinavir,
N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide,
Lopinavir,
ABT-378,
192725-17-0,
Aluviran,
Kaletra,
ABT 378,
Koletra,
A 157378.0,
A-157378.0,
RS-346,
UNII-2494G1JF75,
CHEBI:31781,
Lopinavir (ABT-378),
(alphaS)-Tetrahydro-N-((alphaS)-alpha-((2S,3S)-2-hydroxy-4-phenyl-3-(2-(2,6-xylyloxy)acetamido)butyl)phenethyl)-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide,
LPV,
A 157378,
A-157378-0,
2494G1JF75,
N-{1-BENZYL-4-[2-(2,6-DIMETHYL-PHENOXY)-ACETYLAMINO]-3-HYDROXY-5-PHENYL-PENTYL}-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRAMIDE,
NCGC00164576-02,
DSSTox_CID_26456,
DSSTox_RID_81630,
DSSTox_GSID_46456,
(1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide,
(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide,
(2S)-N-[(1S,3S,4S)-1-benzyl-4-[[2-(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-pentyl]-3-methyl-2-(2-oxohexahydropyrimidin-1-yl)butanamide,
(alphaS)-N-[(1S,3S,4S)-4-[[2-(2,6-Dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide,
(S)-N-((2S,4S,5S)-5-(2-(2,6-dimethylphenoxy)acetamido)-4-hydroxy-1,6-diphenylhexan-2-yl)-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide,
1(2H)-Pyrimidineacetamide, N-((1S,3S,4S)-4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahyrdo-alpha-1-methylethyl)-2-oxo-, (alphaS)-,
AB1,
SMR002529581,
Lopinavir [USAN:INN:BAN],
CAS-192725-17-0,
koletr,
Lopinavir (JAN/USAN/INN),
ABT-378, LOPINAVIR,
HSDB 8138,
1mui,
2qhc,
2rkf,
2rkg,
3ogq,
Lopinavir [USAN:USP:INN:BAN],
AIDS032937,
(2S)-N-((1S,3S,4S)-1-benzyl-4-{[(2,6-dimethylphenoxy)acetyl]amino}-3-hydroxy-5-phenylpentyl)-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide,
(2S)-N-[(1S,3S,4S)-1-benzyl-4-{[(2,6-dimethylphenoxy)acetyl]amino}-3-hydroxy-5-phenylpentyl]-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide,
Lopinavir & PLGA,
ABT 157378,
2o4s,
2q5k,
4l1a,
Lopinavir, ABT 378,
AC1L3OPJ,
CHEMBL729,
LPV & AAG,
SCHEMBL21775,
MLS003915624,
MLS004774152,
MLS006011206,
N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide,
DTXSID8046456,
CTK8E9936,
AOB1042,
KJHKTHWMRKYKJE-SUGCFTRWSA-N,
BCPP000184,
KS-000000TF,
ZINC3951740,
Tox21_112204,
BDBM50180655,
Lopinavir & alpha1-acid glycoprotein,
MFCD22628840,
s1380,
AKOS025243115,
Lopinavir & Poly-lactide-co-glycolide,
Tox21_112204_1,
AN-6726,
BCP9000857,
CS-2077,
DB01601,
KS-1436,
RTR-008945,
NCGC00164576-01,
NCGC00164576-03,
NCGC00164576-04,
HY-14588,
AB0071033,
LS-173766,
TR-008945,
SW219767-1,
C12871,
D01425,
24233-EP2298761A1,
24233-EP2298783A1,
24233-EP2314590A1,
AB01274785-01,
AB01274785_02,
111995-EP2272516A2,
111995-EP2298761A1,
111995-EP2298783A1,
SR-01000931910,
J-521653,
SR-01000931910-2,
BRD-K99451608-001-02-4,
(2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide,
(2S)-N-[(2S,4S,5S)-5-{[(2,6-dimethylphenoxy)acetyl]amino}-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide,
1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-.alpha.-(1-methylethyl)-2-oxo-, (aS)-,
1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)- (9CI),
1(2H)-pyrimidineacetamide, N-[(1S,3S,4S)-4-[[2-(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)-,
1(2H)-Pyrimidineacetamide, N-[4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, [1S-[1R*(R*),3R*,4R*]]-,
1(2H)-pyrimidineacetamide,N-((1S,3S,4S)-4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-1-methylethyl)-2-oxo-,(alphaS)-,
Aluvia,
Lopimune,
Mixture Name,
Kaletra (TN),
Aluvia (TN),
Component of Kaletra,
D0U5GB,
cc-620,
ABT378,
C37H48N4O5,
CID92727,
lopinavir-ritonavir drug combination,
MFCD22373646,
C37-H48-N4-O5,
CS-O-30497,
A2584,
A8204,
A10537,
C112035,
C558899,
D061466,
A157378.0,
Lopinavir, 99%, HIV protease inhibitor - 10mg 10mg,
(2S)-N-[(2R,4S,5S)-5-[[2-(2,6-DIMETHYLPHENOXY)ACETYL]AMINO]-4-HYDROXY-1,6-DIPHENYL-HEXAN-2-YL]-3-METHYL-2-(2-OXO-1,3-DIAZINAN-1-YL)BUTANAMIDE,
(S)-N-((2R,4S,5S)-5-(2-(2,6-Dimethylphenoxy)acetamido)-4-hydroxy-1,6-diphenylhexn-2-yl)-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide,
1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)-(9CI),